Emerging Company Profile
Aulos: Tackling the IL-2 space with computational biology
Emerging Company Profile: Aulos believes its computationally designed mAb will stand out in IL-2
Apple Tree-backed Aulos believe its computationally designed mAb will stand out in the IL-2 crowd.
Apple Tree Partners launched Aulos into the crowded IL-2 space last week with a $40 million series A round and a computationally designed IL-2-binding antibody it thinks could